ERBB2 and cancer: So far, EMA approved five anti-CD20 rituximab, seven anti-human epidermal growth factor receptor 2 (HER-2) trastuzumab, and eight anti-vascular endothelial growth factor (VEGF) bevacizumab anti-cancer biosimilars; FDA approved, respectively, three, five, and four.9